- Home
- XGN vs VNDA Comparison
XGN vs VNDA Comparison
Compare XGN & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XGN
- VNDA
- Stock Information
- Founded
- XGN 2002
- VNDA 2002
- Country
- XGN United States
- VNDA United States
- Employees
- XGN N/A
- VNDA N/A
- Industry
- XGN Medical Specialities
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- XGN Health Care
- VNDA Health Care
- Exchange
- XGN Nasdaq
- VNDA Nasdaq
- Market Cap
- XGN 253.9M
- VNDA 260.0M
- IPO Year
- XGN 2019
- VNDA 2006
- Fundamental
- Price
- XGN $7.47
- VNDA $4.92
- Analyst Decision
- XGN Strong Buy
- VNDA Strong Buy
- Analyst Count
- XGN 6
- VNDA 3
- Target Price
- XGN $13.67
- VNDA $14.00
- AVG Volume (30 Days)
- XGN 460.9K
- VNDA 996.9K
- Earning Date
- XGN 11-04-2025
- VNDA 10-29-2025
- Dividend Yield
- XGN N/A
- VNDA N/A
- EPS Growth
- XGN N/A
- VNDA N/A
- EPS
- XGN N/A
- VNDA N/A
- Revenue
- XGN $63,599,000.00
- VNDA $212,074,000.00
- Revenue This Year
- XGN $22.50
- VNDA $14.32
- Revenue Next Year
- XGN $14.75
- VNDA $37.05
- P/E Ratio
- XGN N/A
- VNDA N/A
- Revenue Growth
- XGN 14.08
- VNDA 11.12
- 52 Week Low
- XGN $2.67
- VNDA $3.81
- 52 Week High
- XGN $12.23
- VNDA $5.70
- Technical
- Relative Strength Index (RSI)
- XGN 18.36
- VNDA 52.61
- Support Level
- XGN $9.19
- VNDA $4.72
- Resistance Level
- XGN $8.35
- VNDA $5.46
- Average True Range (ATR)
- XGN 0.59
- VNDA 0.23
- MACD
- XGN -0.27
- VNDA 0.06
- Stochastic Oscillator
- XGN 0.59
- VNDA 53.36
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.